Loading…
Karyopharm Therapeutics Inc. is projected to rise to $11.86 by 2027, a +15% move from its current price of $10.34. KPTI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $9.98 | $10.35 | $10.73 | +0.10% |
| Jul 13 | $9.85 | $10.36 | $10.90 | +0.20% |
| Jul 14 | $9.75 | $10.37 | $11.04 | +0.30% |
| Jul 15 | $9.66 | $10.38 | $11.16 | +0.41% |
| Jul 16 | $9.59 | $10.39 | $11.26 | +0.51% |
| Jul 17 | $9.53 | $10.40 | $11.36 | +0.61% |
| Jul 18 | $9.47 | $10.41 | $11.45 | +0.71% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.47 | $10.41 | $11.45 | +0.71% |
| Week 2 | $9.17 | $10.49 | $12.00 | +1.43% |
| Week 3 | $8.96 | $10.56 | $12.45 | +2.15% |
| Week 4 | $8.79 | $10.64 | $12.87 | +2.88% |
| Week 5 | $8.66 | $10.71 | $13.25 | +3.61% |
| Week 6 | $8.55 | $10.79 | $13.62 | +4.34% |
| Week 7 | $8.45 | $10.87 | $13.98 | +5.09% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company that discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company develops novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for adult patients with multiple myeloma; in combination with dexamethasone for relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreements with Menarini Group to develop and commercialize selinexor for human oncology indications; with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for non-oncology indications; and a distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc.
The company also has a collaboration with Bristol Myers Squibb to evaluate mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Karyopharm Therapeutics Inc. trades as KPTI and has a current price of $10.67 with a market cap of $241.81M, ranking 3679. The price sits against a defined technical backdrop, with a 50-day moving average of $9.02 and a 200-day moving average of $7.48.
The current price is above both moving averages, indicating a constructive near-term backdrop. The overall price outlook is bullish, supported by a multi-year forecast that guides the path from a near-term level around $10.67 in 2026 to substantially higher levels by 2050.
A major floor 49.6% below — a decisive break under it would weaken the trend.
The nearest floor, 17.8% below — buyers have tended to step in here.
The nearest ceiling, 3.2% above — a clean break opens room to run.
A major ceiling 16.1% above — clearing it would confirm fresh momentum.
Key KPTI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KPTI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.18 | Buy | $10.19 | Buy |
| MA 10 | $10.01 | Buy | $9.99 | Buy |
| MA 20 | $9.65 | Buy | $9.71 | Buy |
| MA 50 | $9.09 | Buy | $9.17 | Buy |
| MA 100 | $8.61 | Buy | $8.59 | Buy |
| MA 200 | $7.52 | Buy | $8.01 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.34 | Neutral |
| Stoch RSI (14) | 61.97 | Neutral |
| CCI (20) | 121.79 | Buy |
| Williams %R (14) | -19.76 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 7.15 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 80.24 | Sell |
| TRIX (15) | 0.46 | Buy |
| Awesome (5,34) | 0.83 | Buy |
| Ultimate (7,14,28) | 63.32 | Neutral |
| Momentum (10) | 0.88 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 10.51 | Sell |
| ADX (14) | 13.89 | Neutral |
| ATR (14) | 0.32 | Info |
The 30-day technical picture is bullish. The stock’s RSI is 60, trading above the common mid-point and signaling steady momentum. It sits above the SMA50 of $9.02 and above the SMA200 of $7.48, which reinforces a constructive near-term trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.21 | $10.34 | $15.79 | 0% | Neutral | |
| $9.17 | $11.86 | $16.40 | +15% | Neutral | |
| $9.80 | $13.18 | $19.09 | +27% | Bullish | |
| $10.22 | $14.19 | $21.31 | +37% | Bullish | |
| $10.59 | $15.12 | $23.40 | +46% | Bullish | |
| $13.09 | $19.18 | $30.47 | +85% | Bullish | |
| $14.95 | $22.45 | $36.51 | +117% | Bullish | |
| $16.25 | $24.98 | $41.49 | +142% | Bullish | |
| $16.71 | $26.26 | $44.47 | +154% | Bullish | |
| $15.95 | $25.59 | $44.12 | +147% | Bullish | |
| $23.52 | $41.64 | $77.33 | +303% | Bullish | |
| $35.88 | $75.79 | $156.63 | +633% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.21 | $10.34 | $12.60 | +0.00% |
| August 2026 | $9.32 | $11.09 | $13.63 | +7.30% |
| September 2026 | $9.44 | $11.34 | $14.14 | +2.21% |
| October 2026 | $9.34 | $11.32 | $14.28 | -0.19% |
| November 2026 | $9.67 | $11.79 | $15.03 | +4.20% |
| December 2026 | $10.00 | $12.27 | $15.79 | +4.07% |
Click any year to see its month-by-month KPTI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Karyopharm Therapeutics Inc.'s 2026 outlook centres on $10.34, within a $5.21 to $15.79 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, KPTI could reach as high as $16.40, with a base case around $11.86 and support toward $9.17 — roughly +15% from $10.34. Price action looks broadly range-bound.
Expect KPTI to range from $9.80 to $19.09 through 2028. The $13.18 average target implies a +27% move from current prices. That is up +11% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The KPTI price prediction for 2029 points to an average of $14.19 (low $10.22, high $21.31) — a potential gain of +37% on today's $10.34. Momentum favours further upside here.
In 2030, KPTI is projected to trade between $10.59 and $23.40, averaging $15.12 — a potential gain of +46% from today's $10.34. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Karyopharm Therapeutics Inc.'s 2031 outlook centres on $19.18, within a $13.09 to $30.47 range. That is up +27% on the projected 2030 average. That marks a +85% change versus current levels. Momentum favours further upside here.
By 2032, KPTI could reach as high as $36.51, with a base case around $22.45 and support toward $14.95 — roughly +117% from $10.34. Buyers look set to stay in control over this stretch.
Expect KPTI to range from $16.25 to $41.49 through 2033. The $24.98 average target implies a +142% move from current prices. That is up +11% on the projected 2032 average. Momentum favours further upside here.
The KPTI price prediction for 2034 points to an average of $26.26 (low $16.71, high $44.47) — a potential gain of +154% on today's $10.34. Buyers look set to stay in control over this stretch.
In 2035, KPTI is projected to trade between $15.95 and $44.12, averaging $25.59 — a potential gain of +147% from today's $10.34. That is -3% versus the projected 2034 average. Momentum favours further upside here.
Karyopharm Therapeutics Inc.'s 2040 outlook centres on $41.64, within a $23.52 to $77.33 range. That is up +63% on the projected 2035 average. That marks a +303% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, KPTI could reach as high as $156.63, with a base case around $75.79 and support toward $35.88 — roughly +633% from $10.34. Momentum favours further upside here.
Investing $1,000 in KPTI today (≈ 96.711799 KPTI) could be worth
$7,330.03
+$6,330.03 (+633%) by 2050 · US Dollar
Based on the average projected KPTI price of $75.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KPTIwould be worth at today's price.
$1,000 invested in KPTI on Jul 10, 2025 (≈ 200 KPTI) would be worth
$2,068
+$1,068 (+106.8%) today · 2.07× · US Dollar
Based on a KPTI entry price of $5 vs. today's $10.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.6 | $1,077.08 | +7.7% |
| 1 month ago | $9.11 | $1,135.02 | +13.5% |
| 3 months ago | $8 | $1,292.5 | +29.3% |
| 6 months ago | $8.19 | $1,261.75 | +26.2% |
| 1 year ago | $5 | $2,068 | +106.8% |
| All time (5.0y) ago | $145.95 | $70.85 | -92.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KPTI forecast.
Our base-case forecast reaches $21.00 around 2032.
Implied market cap at $21.00: $475.92M
Multi-year forecasts show a rising average price and meaningful upside potential. The 2026 forecast averages $10.67 with a 0 ROI, followed by rising forward expectations: 2027 avg $12.28 (ROI 15.1), 2028 avg $13.80 (ROI 29.3), 2029 avg $14.91 (ROI 39.7), and 2030 avg $15.94 (ROI 49.4). The trajectory continues higher in later years, with 2031 avg $20.58 (ROI 92.9), 2032 avg $24.05 (ROI 125.4), 2033 avg $26.72 (ROI 150.4), 2034 avg $28.25 (ROI 164.8), and 2035 avg $27.40 (ROI 156.8).
By 2040, the forecast shows an avg of $45.43 (ROI 325.8) and by 2050 an avg of $83.02 (ROI 678.1). These are estimates and carry uncertainty, but they depict a bullish longer-term path.
Tap a question to reveal the answer.
Market cap is $241.81M and rank is 3679.
Avg $15.94; min $11.09; max $24.85; ROI 49.4; sentiment BULLISH.
Avg $45.43; min $25.27; max $85.28; ROI 325.8; sentiment BULLISH.
Avg $83.02; min $38.37; max $173.71; ROI 678.1; sentiment BULLISH. Near-term indicators: RSI14 60, SMA50 $9.02, SMA200 $7.48, 30-day range $8.36-$13.61, support $8.50, resistance $10.67.
Karyopharm Therapeutics Inc. Community Discussion
0Share your Karyopharm Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.